Optimizing the benefit of multiple sclerosis therapy: the importance of treatment adherence.
about
Teriflunomide for multiple sclerosisTeriflunomide for multiple sclerosisTreatment adherence and other patient-reported outcomes as cost determinants in multiple sclerosis: a review of the literatureAdherence to interferon β-1b treatment in patients with multiple sclerosis in SpainThe Value of Medicines: A Crucial but Vague Concept.Single-use autoinjector for peginterferon-β1a treatment of relapsing-remitting multiple sclerosis: safety, tolerability and patient evaluation data from the Phase IIIb ATTAIN study.An open-label, multicenter study to evaluate the safe and effective use of the single-use autoinjector with an Avonex® prefilled syringe in multiple sclerosis subjectsTreatment discontinuation in multiple sclerosis: The French Web-based survey ALLIANCEPrognostic factors for long-term outcomes in relapsing-remitting multiple sclerosisComparative Effectiveness Research of Disease-Modifying Therapies for the Management of Multiple Sclerosis: Analysis of a Large Health Insurance Claims Database.Enhanced patient support services improve patient persistence with multiple sclerosis treatment.Management of flu-like syndrome with cetirizine in patients with relapsing-remitting multiple sclerosis during therapy with interferon beta: Results of a randomized, cross-over, placebo-controlled pilot study.Classical immunomodulatory therapy in multiple sclerosis: how it acts, how it works.Oral therapies for multiple sclerosis: a review of agents in phase III development or recently approved.Patient preferences for disease-modifying drugs in multiple sclerosis therapy: a choice-based conjoint analysis.Comparison of adherence and persistence among multiple sclerosis patients treated with disease-modifying therapies: a retrospective administrative claims analysis.Treatment adherence and transitioning youth in pediatric multiple sclerosisLong-term persistence with injectable therapy in relapsing-remitting multiple sclerosis: an 18-year observational cohort studyPatient perceptions of multiple sclerosis and its treatmentReasons for discontinuation of subcutaneous interferon β-1a three times a week among patients with multiple sclerosis: a real-world cohort studyA discrete-choice experiment to determine patient preferences for injectable multiple sclerosis treatments in Germany.Patient Preferences for Injectable Treatments for Multiple Sclerosis in the United States: A Discrete-Choice Experiment.Perspectives and experiences of Dutch multiple sclerosis patients and multiple sclerosis-specialized neurologists on injectable disease-modifying treatment.A mechanistically novel, first oral therapy for multiple sclerosis: the development of fingolimod (FTY720, Gilenya).Health insurance affects the use of disease-modifying therapy in multiple sclerosis.Adherence to first-line disease-modifying therapy for multiple sclerosis in kuwaitTreatment discontinuation and disease progression with injectable disease-modifying therapies: findings from the north american research committee on multiple sclerosis database.Facilitating medication adherence in patients with multiple sclerosis.Retrospective US database analysis of persistence with glatiramer acetate vs. available disease-modifying therapies for multiple sclerosis: 2001-2010.An evaluation of adherence in patients with multiple sclerosis newly initiating treatment with a self-injectable or an oral disease-modifying drug.Managing MS in a changing treatment landscape.A new electronic device for subcutaneous injection of IFN-β-1a.Adherence and persistence among multiple sclerosis patients after one immunomodulatory therapy failure: retrospective claims analysis.RebiSmart™ (version 1.5) device for multiple sclerosis treatment delivery and adherence.Fingolimod for multiple sclerosis: a review for the specialist nurse.Fostering adherence to injectable disease-modifying therapies in multiple sclerosis.PEGylated IFNβ-1a in the treatment of multiple sclerosis.Comparison of fingolimod and dimethyl fumarate in the treatment of multiple sclerosis: Two-year experience.Determinants of high cost in multiple sclerosis patients: a claims and chart review study.Enrolling and keeping participants in multiple sclerosis self-management interventions: a systematic review and meta-analysis.
P2860
Q24198146-B2EE214B-76E2-46C0-A2CD-E262E52F6145Q24202177-EADD66E3-E98B-4A2D-9395-F39C32A9F79BQ27015089-1271CEE2-FDDF-4B1A-9946-B852568E427EQ28729921-339D5864-A1AB-4FD4-A6C0-EB85F8D4044BQ30248857-5FA80174-B5B9-4CAC-AFE7-1D27AD624995Q30839407-D60F03F4-B562-4AC1-BA83-3418DE6514F3Q31038370-A1C33F3E-980B-4029-B4AA-0A631937E279Q33692801-CE8CBBD6-4FB9-47D6-A029-9B1738BC2628Q33693097-B1510DE5-F10D-452C-805E-1BD743A32855Q33736215-3E1BEA42-A89B-4D82-BF79-31EBFAA4A245Q33774117-AD91B171-918F-42F8-BC9B-0CFAC400A050Q33883508-9A13B710-E6EB-4913-97D8-A77D6E6C4558Q33960392-C1788F60-78EA-49E7-9C2B-C960424B8DDAQ34153221-C9D43E32-C338-4864-AA4C-F601EA7414D1Q34446128-56B31C26-3379-493E-ABF3-71A34BAAE880Q34681746-A9218FC9-BC1E-496E-94E8-36AA25631DE9Q35182797-AA35219D-4650-4397-8EB0-3EBD97812AD6Q35388991-F7594537-1F8F-4654-B929-B2FDBAA17C3DQ35905945-A5AB0A2E-01CD-4BD1-A668-E236B883DE3CQ36320930-65D1519C-5034-484A-A61E-72B5A1994078Q36667801-09F557D4-8549-40E0-AD99-38DF3EDD0295Q36698871-554EF1F4-66B0-4E96-8F1E-2AB2E2F38B79Q36861884-AD07B1DB-008A-4E48-9988-C02F3A991D5BQ36960355-A05D4118-3E6D-4A67-8EF6-9A57D9EBA868Q37158954-D4A6FF3C-F3DF-4B76-A07A-13573ABA50CFQ37442166-08DB8223-45F2-47A7-BB6F-D2CAB9846FDDQ37442365-B2553F83-E190-45B1-B34D-E80C917D3D0AQ37442437-BD8B6566-0E17-4B40-B85E-03A675B31F08Q37501092-D01DE777-23F0-4AAA-8F59-544763CEB2BAQ37573148-34B3508F-615D-4EC7-AC75-B721DFBBC791Q37857752-DFDE620E-8635-4603-A3B3-657349CDB39DQ37897572-66750229-619E-4F2C-8E30-C260DF29736BQ37922644-B48C34AB-9E18-4DE4-9D6A-973D404EFD1AQ38068514-6DA62851-A709-4F65-88E5-01AF4E3598DCQ38220605-7EE6D3AC-AFBD-4555-BBDE-352492E39D55Q38238548-F7FE850A-A8D5-4DDF-987B-569F131DEE79Q38513495-9E4332AC-7D6D-4DA0-A4BD-AA25012040E3Q38608929-EFD26B7B-DC1E-47CD-9A68-8F543245CC1CQ38840408-B87A21E5-50D5-45C7-B1EB-89770F774970Q38892908-DBB51306-598A-4348-8A27-23AC06411283
P2860
Optimizing the benefit of multiple sclerosis therapy: the importance of treatment adherence.
description
2010 nî lūn-bûn
@nan
2010 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Optimizing the benefit of mult ...... rtance of treatment adherence.
@ast
Optimizing the benefit of mult ...... rtance of treatment adherence.
@en
type
label
Optimizing the benefit of mult ...... rtance of treatment adherence.
@ast
Optimizing the benefit of mult ...... rtance of treatment adherence.
@en
prefLabel
Optimizing the benefit of mult ...... rtance of treatment adherence.
@ast
Optimizing the benefit of mult ...... rtance of treatment adherence.
@en
P2860
P356
P1476
Optimizing the benefit of mult ...... rtance of treatment adherence.
@en
P2093
Francesco Patti
P2860
P356
10.2147/PPA.S8230
P407
P577
2010-02-04T00:00:00Z